Jaguar Health, Inc. $(JAGX)$ has announced updates regarding their clinical development program for crofelemer, aimed at treating intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF). The company is conducting two placebo-controlled Phase 2 studies in the United States, European Union, and Middle East/North Africa regions. Enrollment for the Phase 2 study on crofelemer's efficacy in pediatric MVID patients has reached approximately 25%, with completion expected in mid-2026. Additionally, enrollment for the SBS-IF study in adults has surpassed 10%. Initial proof-of-concept results from independent investigator-initiated trials indicate a reduction in required total parenteral nutrition for patients with MVID and SBS by up to 27% and 12.5%, respectively. Further data from these trials are anticipated as enrollment continues.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.